| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 7 | -1.26M | 100% | $10.37 | -$13M |
| Net | -7 | -1.26M | -100% | -$13M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Qian Zhang | Associate VP, Research | $1.98M | Feb 17, 2023 | ||
| Aladar Szalay | 10%+ Owner | $1.76M | -$9.18M | -84% | Sep 9, 2024 |
| John Thomas | Director | $1.07M | -$346K | -24.4% | Aug 1, 2024 |
| Thomas Zindrick | President and CEO, Director | $786K | May 29, 2024 | ||
| Gabe Woodward | Director | $175K | Feb 17, 2023 | ||
| James L. Tyree | Director | $124K | -$123K | -50% | Sep 11, 2024 |
| Lourie S. Zak | Chief Financial Officer | $114K | May 29, 2024 | ||
| John W. Smither | Director | $112K | Aug 1, 2024 | ||
| Mary Mirabelli | Director | $110K | Aug 1, 2024 | ||
| Ralph Smalling | Head of Regulatory | $48.8K | May 29, 2024 | ||
| Joseph Cappello | VP, Pharmaceutical Development | $44.4K | Feb 19, 2024 | ||
| Sean Ryder | General Counsel | $41.1K | -$312K | -88.3% | May 29, 2024 |
| Caroline Jewett | Head of Quality | $34.3K | -$10.5K | -23.5% | Feb 19, 2024 |
| Doug Samuelson | Vice President, Finance | $32.6K | Sep 11, 2023 | ||
| Yong Yu | VP, Clinical Trial Operations | $23K | -$2.01M | -98.9% | May 29, 2024 |
| Paul Scigalla | Chief Medical Officer | Jan 25, 2023 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|